- Conditions
- Clostridioides Difficile Infection Recurrence
- Interventions
- Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
- Other
- Lead sponsor
- Bactolife A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 12,775
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Lenalidomide, Dexamethasone, Anticoagulants
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation
- Procedure · Device
- Lead sponsor
- Vektor Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Jonesboro, Arkansas • Clearwater, Florida • Jacksonville, Florida + 9 more
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
- Conditions
- Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- Interventions
- OTS167PO
- Drug
- Lead sponsor
- OncoTherapy Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 8
- States / cities
- Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more
- Conditions
- Thrombocytopenia
- Interventions
- Avatrombopag
- Drug
- Lead sponsor
- Sobi, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2018 – 2019
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 65
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- cilengitide, temozolomide, radiation therapy, laboratory biomarker analysis, pharmacological study
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- Coronary Artery Disease
- Interventions
- ElucidVivo
- Device
- Lead sponsor
- Elucid Bioimaging Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Atlanta, Georgia • Fort Wayne, Indiana + 5 more
- Conditions
- Coronary Artery Disease
- Interventions
- COBRA PzF
- Device
- Lead sponsor
- CeloNova BioSciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 22
- States / cities
- Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Faster-acting insulin aspart, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pulmonary Tuberculosis
- Interventions
- rifampin, rifapentine
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
- Interventions
- IPI-549 (eganelisib), Nivolumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 11
- States / cities
- San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
- Conditions
- Cocaine-Related Disorders
- Interventions
- acoustic startle testing
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Hepatitis C
- Interventions
- TMC435, PSI-7977 (GS7977), Ribavirin
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 22
- States / cities
- Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more
- Conditions
- Oral Dystonia, Tardive Dystonia
- Interventions
- Low Dose - AbobotulinumtoxinA
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- TV-44749, Oral olanzapine
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more
- Conditions
- Leukemia
- Interventions
- nelarabine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 107
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Crohn Disease
- Interventions
- Diet
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • San Francisco, California • Denver, Colorado + 27 more
- Conditions
- B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
- Interventions
- VELCADE and rituximab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Fort Myers, Florida • Atlanta, Georgia + 10 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic
- Interventions
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
- Conditions
- Stroke, Ischemic
- Interventions
- wearable wristband model, Samsung Galaxy Watch 6, Standard of care extended ECG monitoring
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more